Tyra Biosciences (TYRA) Assets (2020 - 2026)
Tyra Biosciences' (TYRA) quarterly Assets came in at $412.0 million in Q1 2026, up 19.96% YoY from $343.5 million in Q1 2025, and up 45.8% on a QoQ basis from $282.6 million in Q4 2025.
Tyra Biosciences (TYRA) Assets (2020 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 7 years of Assets data on file, last reported at $412.0 million in Q1 2026.
- Quarterly Assets rose 19.96% year-over-year to $412.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $412.0 million (up 19.96% YoY) and the FY2025 annual result came in at $282.6 million, down 22.27% from the prior year.
- Assets rose to $412.0 million in Q1 2026, from $282.6 million in the prior quarter.
- In the past five years, Assets ranged from a high of $412.0 million in Q1 2026 to a low of $225.9 million in Q4 2023.
- A 5-year average of $311.8 million and a median of $299.0 million in 2022 frame the typical range for Assets.
- Annual changes were most pronounced in 2024 — Assets surged 60.97% — and 2025, when it fell 22.27%.
- Tracing TYRA's Assets over 5 years: stood at $266.2 million in 2022, then slipped by 15.15% to $225.9 million in 2023, then surged by 60.97% to $363.6 million in 2024, then slipped by 22.27% to $282.6 million in 2025, then surged by 45.8% to $412.0 million in 2026.
- The last three Assets figures came in at $412.0 million (Q1 2026), $282.6 million (Q4 2025), and $301.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - | 383.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 383.36 Mn |
| Mar 31, 2026 | 412.04 Mn |
| Dec 31, 2025 | 282.61 Mn |
| Sep 30, 2025 | 301.85 Mn |
| Jun 30, 2025 | 321.50 Mn |
| Mar 31, 2025 | 343.48 Mn |
| Dec 31, 2024 | 363.56 Mn |
| Sep 30, 2024 | 380.59 Mn |
| Jun 30, 2024 | 392.46 Mn |
| Mar 31, 2024 | 404.74 Mn |
| Dec 31, 2023 | 225.86 Mn |
| Sep 30, 2023 | 238.36 Mn |
| Jun 30, 2023 | 250.01 Mn |
| Mar 31, 2023 | 255.06 Mn |
| Dec 31, 2022 | 266.18 Mn |
| Sep 30, 2022 | 275.99 Mn |
| Jun 30, 2022 | 287.12 Mn |
| Mar 31, 2022 | 298.97 Mn |
| Dec 31, 2021 | 306.70 Mn |
| Sep 30, 2021 | 315.97 Mn |